In the Claims:

Kindly cancel claim 21 without prejudice to the filing of any appropriate continuation applications.

Please amend the claims as follows:

2. (Amended) The compound of claim 1 wherein the base sequence binds to the target portion of the nucleic acid in a manner to inhibit the expression of angiogenin.

3. (Amended) The compound of claim 2 wherein the oligonucleotide analog comprises a modification selected from the group consisting of a modified internucleotide linkage, a modified purine or pyrimidine moiety, a modified sugar moiety, a modified 5' hydroxyl moiety, a modified 3' hydroxyl moiety and a modified 2' hydroxyl moiety.

4. (Amended) The compound of claim 3 wherein the modified internucleotide linkage comprises a substituent having an improved aqueous or lipid solubility or improved resistance to nuclease digestion as compared to an unmodified compound.

5. (Amended) The compound of claim 4 wherein the modified internucleotide linkage is selected from the group consisting of phosphorothioate, N-alkyl phosphoramidates, cycloalkyl phosphoramidates, alkyl phosphonates, cycloalkyl phosphonates, phosphodiester, phosphotriester, C_1 - C_4 alkyl, cycloalkyl, short chain heteroatomic backbone, short chain heterocyclic backbone, morpholino backbone, polyprotein-nucleic acid backbone, peptide-

nucleic acid backbone, polyamide, CH_2-NH-O-CH_2, CH_2-N(CH_3)-O-CH_2, CH_3-O-N(CH_3)-CH_2, CH_2-N(CH_3)-N(CH_3)-CH_2, and O-N(CH_3)-CH_2-CH_2.

8. (Amended) The compound of claim 3 wherein the modified 5' or 3' hydroxyl moiety is selected from the group consisting of C_{1-4} alkoxy, intercalating agent, peptide, enzyme, and ribozyme.

9. (Amended) The compound of claim 3 wherein the modified 2' hydroxyl moiety is selected from the group consisting of OH, SH, SCH_2, OCH_3, F, OCN, OCH_6CH_3, OCH_3OCH_3, $OCH_3O(CH_2)_n$ CH_3, $O(CH_2)_nNH_2$, O $(CH_2)_nCH_3$, where n is from 1 to about 10; C_1 to C_{10} lower alkyl, substituted lower alkyl, substituted lower alkaryl substituted lower aralkyl; Cl; Br; CN; CF_3; OCF_3; O, S, N-alkyl; O, S, N-alkenyl; $SOCH_3$; SO_2CH_3; ONO_2; NO_2; N_3; NH_2; heterocycloalkyl, alkaryl; aminoalkylamino; polyalkylamino; substituted silyl: an RNA cleaving group; a cholesteryl group; a conjugate; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide as compared to an unmodified compound; and a group for improving the pharmacodynamic properties of an oligonucleotide as compared to an unmodified compound.

13. (Amended) A compound for inhibiting expression of angiogenin having the formula:

5'



3'

wherein

X is selected from the group consisting of O, S, and C_{1-4} alkyl;

B is selected from the group consisting of adenine, guanine, cytosine, and thymine, selected such that the oligonucleotide has a complementary base sequence with a portion of a target nucleic acid strand coding for angiogenin thereby inhibiting expression thereof;

R_1 is selected from the group consisting of H, C_{1-4} alkyl, intercalating agent, peptide, enzyme, and ribozyme;

R_2 is selected from the group consisting of H, OH, SH, SCH_2, OCH_3, F, OCN, OCH_6CH_3, OCH_3OCH_3, $OCH_3O(CH_2)_p\,CH_3$, $O(CH_2)_pNH_2$, $O\,(CH_2)_pCH_3$, where p is from 1 to about 10; C_1 to C_{10} lower alkyl, substituted lower alkyl, substituted lower alkaryl, substituted lower aralkyl; Cl; Br; CN; CF_3; OCF_3; O, S, N-alkyl; O, S, N-alkenyl; $SOCH_3$; SO_2CH_3; ONO_2; NO_2; N_3; NH_2; heterocycloalkyl, alkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a cholesteryl group; a conjugate; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide as compared to an

unmodified oligonucleotide; and a group for improving the pharmacodynamic properties of an oligonucleotide as compared to an unmodified oligonucleotide; and

n is 5 to 100.

Please add the following new claims:

--22. (NEW) The compound of claim 5 wherein the phosphorothioate is selected from the group consisting of alkyl phosphorothioate, cycloalkyl phosphorothioate, and phosphorodithioates.

23. (NEW) The compound of claim 8 wherein the intercalating agent is a substituted acridine.

24. (NEW) The compound of claim 13 wherein the intercalating agent is a substituted acridine.

25. (NEW) The compound of claim 23 wherein the substituted acridine is selected from the group consisting of 2-methoxy-6-chloro-9-pentylaminoacridine, N-(6-chloro-2-methoxyacridinyl)-O-methoxydiisopropylaminophosphinyl-3-aminopropanol, and N-(6 chloro-2-methoxyacridinyl)-O-methoxydiisopropylaminophosphinyl-5-aminopentanol.

26. (NEW) The compound of claim 24 wherein the substituted acridine is selected from the group consisting of 2-methoxy-6-chloro-9-pentylaminoacridine, N-(6-chloro-2-

methoxyacridinyl)-O-methoxydiisopropylaminophosphinyl-3-aminopropanol, and N-(6 chloro-2-methoxyacridinyl)-O-methoxydiisopropylaminophosphinyl-5-aminopentanol.--